| Literature DB >> 26599049 |
Martina Sattlecker1,2, Mizanur Khondoker1,2, Petroula Proitsi1,2, Stephen Williams3, Hilkka Soininen4, Iwona Kłoszewska5, Patrizia Mecocci6, Magda Tsolaki7, Bruno Vellas8, Simon Lovestone1,2, Richard Jb Dobson1,2.
Abstract
Biomarkers of Alzheimer's disease (AD) progression are needed to support the development of urgently needed disease modifying drugs. We employed a SOMAscan assay for quantifying 1,001 proteins in blood samples from 90 AD subjects, 37 stable mild cognitive impaired (MCI) subjects, 39 MCI subjects converting to AD within a year and 69 controls at baseline and one year follow up. We used linear mixed effects models to identify proteins changing significantly over one year with the rate of cognitive decline, which was quantified as the reduction in Mini Mental State Examination (MMSE) scores. Additionally, we investigated proteins changing differently across disease groups and during the conversion from MCI to AD. We found that levels of proteins belonging to the complement cascade increase significantly in fast declining AD patients. Longitudinal changes in the complement cascade might be a surrogate biomarker for disease progression. We also found that members of the cytokine-cytokine receptor interaction pathway change during AD when compared to healthy aging subjects.Entities:
Keywords: Alzheimer’s disease; cognitive decline; complement cascade; cytokine-cytokine receptor interaction; plasma proteins
Mesh：
Substances：
Year: 2016 PMID： 26599049 DOI： 10.3233/JAD-140669
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472